Ciltacabtagene autoleucel greatly reduces risk of disease progression in lenalidomide-refractory MM

mRCC: Atezolizumab after progression with prior ICI treatment shows no benefit and increases toxicity

Effectiveness of a cardiovascular health EHR application for cancer survivors in community oncology practice

ASCO 2023: Head and neck highlights

Cabozantinib with nivolumab/ipilimumab shows superior efficacy compared to cabozantinib alone in soft tissue sarcoma

Baseline liquid biopsy results in treatment efficacy of FOLFIRI/cetuximab in patients with tissue RAS-WT mCRC

Elranatamab shows efficacy in RRMM with prior BCMA-directed treatment

Nivolumab-AVD reduces the risk of disease progression compared to brentuximab vedotin-AVD in advanced Hodgkin lymphoma

HCC: Improvement in RFS for atezolizumab plus bevacizumab vs active surveillance without compromising QoL

Adding ribociclib to endocrine therapy shows an improvement in invasive disease-free survival in HR+/HER2 BC patients

Nine-weeks trastuzumab still effective compared with one year trastuzumab for early-stage HER2 positive breast cancer

ATTRACTION-5: Nivolumab plus chemotherapy as postoperative adjuvant treatment for pStage III G/GEJ cancer